新型胆固醇吸收抑制剂依哲麦布(ezetimibe,EZ)可显著降低患者的低密度脂蛋白胆固醇(LDL-C),升高高密度脂蛋白胆固醇(HDL-C)水平,不良反应较少。EZ与他汀类药物联合应用,有良好的药物协同效应,可避免大剂量他汀潜在的不良反应。如果患者在单用最佳剂量他汀类治疗的情况下没有达标,那么EZ联合他汀类可以是一种合理的治疗。 Ezetimibe (EZ), a new cholesterol absorption inhibitor, significantly decreased LDL-C and HDL-C levels in patients with less adverse reactions. EZ and statins in combination with good synergistic effects of drugs to avoid the potential adverse effects of high-dose statins. If a patient fails to achieve compliance with the best dose of statin alone, then EZ plus statins may be a reasonable treatment.